Effect of Sildenafil on Left Ventricular Function in Pediatric Primary Dilated Cardiomyopathy
Summary
NIH registered observational study NCT07536880 titled 'Effect of Sildenafil on Left Ventricular Function in Pediatric With Primary Dilated Cardiomyopathy.' The study examines sildenafil's effect on left ventricular function in pediatric patients with primary dilated cardiomyopathy, characterized by left ventricular dilation and impaired contraction. The study was registered on April 17, 2026.
What changed
NIH registered a new observational clinical trial (NCT07536880) evaluating sildenafil's effect on left ventricular function in pediatric patients with primary dilated cardiomyopathy. The study focuses on patients with impaired left ventricle fraction shortening less than 28% and left ventricular end diastolic dimension Z-score greater than 2, conditions that can lead to arrhythmias and sudden death.\n\nHealthcare providers and clinical investigators conducting or tracking pediatric heart failure research should note this study's registration. Pharmaceutical companies developing sildenafil or similar therapies for pediatric cardiomyopathies may find this relevant to their product pipelines. No compliance obligations or regulatory deadlines are created by this study registration.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Effect of Sildenafil on Left Ventricular Function in Pediatric With Primary Dilated Cardiomyopathy
Observational NCT07536880 Kind: OBSERVATIONAL Apr 17, 2026
Abstract
Dilated cardiomyopathy (DCM) is a clinical diagnosis characterized by left ventricular or biventricular dilation and impaired contraction that is not explained by abnormal loading conditions.(1) Both inherited predisposition and environmental factors play an important part in the natural history of disease.(1) Cardiomyopathies are group of heart diseases that influence cardiac muscles directly and are not related to hypertension, congenital, valvular and pericardial diseases. The most common type of cardiomyopathy is dilated cardiomyopathy (DCM).(2) Definitions of DCM provided by two major professional organizations (American Heart Association (AHA) and European Society of Cardiology (ESC)) Both organizations agreed that DCM could be clinically defined by the presence of left ventricular dilation and contractile dysfunction in the absence of abnormal loading conditions and severe coronary artery disease.(3) Dilated cardiomyopathy usually manifests as chronic systolic heart failure, which is detected by echocardiography as impaired left ventricle fraction shortening less than 28%, with left ventricular end diastolic dimension Z-score>2 ,leading to arrhythmias and sudden death.(4,5) idiopathic dilated cardiomyopathy (DCM) is characterized by dilatation and impaired contraction of the left ventricle or both ventricles, in the absence of underlying causes such as CAD, valve disease, congenital heart disease, or pericardial disease. Most patients present with symptoms of heart...
Conditions: Cardiomyopathy, Dilated
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.